# Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

> **NCT00556296** · PHASE3 · COMPLETED · sponsor: **New River Pharmaceuticals** · enrollment: 297 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** NRP104
- **DRUG:** NRP104
- **DRUG:** NRp104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00556296
- **Lead sponsor:** New River Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2011-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556296, "Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00556296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*